NO322910B1 - 4-Pyridyl-N-acyl-L-fenylalaniner, anvendelse av disse som medikamenter, farmasoytiske preparater inneholdende slike forbindelser og fremgangsmate for fremstilling av disse. - Google Patents

4-Pyridyl-N-acyl-L-fenylalaniner, anvendelse av disse som medikamenter, farmasoytiske preparater inneholdende slike forbindelser og fremgangsmate for fremstilling av disse. Download PDF

Info

Publication number
NO322910B1
NO322910B1 NO20022650A NO20022650A NO322910B1 NO 322910 B1 NO322910 B1 NO 322910B1 NO 20022650 A NO20022650 A NO 20022650A NO 20022650 A NO20022650 A NO 20022650A NO 322910 B1 NO322910 B1 NO 322910B1
Authority
NO
Norway
Prior art keywords
alkyl
hydrogen
oxo
carbonyl
pyridinyl
Prior art date
Application number
NO20022650A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022650D0 (no
NO20022650L (no
Inventor
Jefferson Wright Tilley
Achyutharao Sidduri
Gerald Lewis Kaplan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20022650D0 publication Critical patent/NO20022650D0/no
Publication of NO20022650L publication Critical patent/NO20022650L/no
Publication of NO322910B1 publication Critical patent/NO322910B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20022650A 1999-12-06 2002-06-05 4-Pyridyl-N-acyl-L-fenylalaniner, anvendelse av disse som medikamenter, farmasoytiske preparater inneholdende slike forbindelser og fremgangsmate for fremstilling av disse. NO322910B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16909099P 1999-12-06 1999-12-06
PCT/EP2000/011979 WO2001042215A1 (en) 1999-12-06 2000-11-29 4-pyridinyl-n-acyl-l-phenylalanines

Publications (3)

Publication Number Publication Date
NO20022650D0 NO20022650D0 (no) 2002-06-05
NO20022650L NO20022650L (no) 2002-06-05
NO322910B1 true NO322910B1 (no) 2006-12-18

Family

ID=22614226

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022650A NO322910B1 (no) 1999-12-06 2002-06-05 4-Pyridyl-N-acyl-L-fenylalaniner, anvendelse av disse som medikamenter, farmasoytiske preparater inneholdende slike forbindelser og fremgangsmate for fremstilling av disse.

Country Status (34)

Country Link
EP (1) EP1244625B1 (ar)
JP (2) JP2003516392A (ar)
KR (1) KR100492111B1 (ar)
CN (1) CN1196682C (ar)
AR (1) AR031083A1 (ar)
AT (1) ATE297895T1 (ar)
AU (1) AU779063B2 (ar)
BR (1) BR0016172A (ar)
CA (1) CA2392566A1 (ar)
CO (1) CO5080771A1 (ar)
CZ (1) CZ20022352A3 (ar)
DE (1) DE60020883T2 (ar)
DK (1) DK1244625T3 (ar)
ES (1) ES2243335T3 (ar)
GC (1) GC0000214A (ar)
HK (1) HK1053470A1 (ar)
HR (1) HRP20020467A2 (ar)
HU (1) HUP0203735A3 (ar)
IL (2) IL149622A0 (ar)
JO (1) JO2281B1 (ar)
MA (1) MA26849A1 (ar)
MX (1) MXPA02005240A (ar)
MY (1) MY128003A (ar)
NO (1) NO322910B1 (ar)
NZ (1) NZ518888A (ar)
PE (1) PE20010960A1 (ar)
PL (1) PL364814A1 (ar)
PT (1) PT1244625E (ar)
RU (1) RU2270193C2 (ar)
TW (1) TWI276629B (ar)
UY (1) UY26470A1 (ar)
WO (1) WO2001042215A1 (ar)
YU (1) YU40502A (ar)
ZA (1) ZA200203762B (ar)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
IL154350A0 (en) 2000-08-18 2003-09-17 Ajinomoto Kk New phenylalanine derivatives
AU2001290303A1 (en) 2000-09-29 2002-04-15 Ajinomoto Co., Inc. Novel phenylalanine derivatives
AU2002354224A1 (en) * 2001-12-13 2003-07-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
EP2615087A3 (en) 2003-12-22 2013-08-07 Ajinomoto Co., Inc. Phenylalanine derivatives
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
ATE430761T1 (de) * 2004-08-16 2009-05-15 Merck & Co Inc Vla-4-antagonisten
JP4784224B2 (ja) 2004-09-24 2011-10-05 味の素株式会社 糖鎖転移方法および糖鎖転移酵素
JP2009531304A (ja) * 2006-02-28 2009-09-03 エラン ファーマシューティカルズ,インコーポレイテッド α−4阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
TW200811164A (en) * 2006-05-12 2008-03-01 Jerini Ag New heterocyclic compounds for the inhibition of integrins and use thereof
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING ALPHA-FETOPROTEIN COMBINED WITH INTEGRIN ANTAGONIST
EP2288715B1 (en) 2008-04-11 2014-09-24 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
JP5735962B2 (ja) * 2009-07-23 2015-06-17 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 新規なアルコキシエノンおよびエナミノケトンおよびその調製方法
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
RU2624731C2 (ru) * 2012-01-27 2017-07-06 Ф. Хоффманн-Ля Рош Аг Конъюгаты антагонистов интегрина для нацеленной доставки к клеткам, экспрессирующим vla-4
MX370666B (es) * 2013-06-11 2019-12-19 Celgene Int Ii Sarl Novedosos moduladores del receptor de péptido tipo glucagón 1 (glp-1).
DK3412660T3 (da) 2016-02-05 2020-11-30 Ea Pharma Co Ltd Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
EP3873900A1 (en) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
WO2020092383A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc Heterocyclic amides as cell adhesion inhibitors
EP1017382B1 (en) * 1997-05-29 2006-03-01 Merck & Co., Inc. (a New Jersey corp.) Biarylalkanoic acids as cell adhesion inhibitors
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
JP2002504534A (ja) * 1998-02-26 2002-02-12 セルテック・セラピューティクス・リミテッド α4インテグリンの阻害剤としてのフェニルアラニン誘導体
GB9811159D0 (en) * 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
DE69915692T2 (de) * 1998-12-22 2005-02-10 Tanabe Seiyaku Co., Ltd. Inhibitoren der alpha-4 beta-1 vermittelten zelladhäsion
US6465513B1 (en) * 1999-01-22 2002-10-15 Elan Pharmaceuticals, Inc. Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4

Also Published As

Publication number Publication date
MA26849A1 (fr) 2004-12-20
JP2008094842A (ja) 2008-04-24
AU779063B2 (en) 2005-01-06
ATE297895T1 (de) 2005-07-15
HK1053470A1 (en) 2003-10-24
EP1244625B1 (en) 2005-06-15
MXPA02005240A (es) 2002-11-07
ZA200203762B (en) 2004-01-28
NO20022650D0 (no) 2002-06-05
NZ518888A (en) 2004-02-27
KR100492111B1 (ko) 2005-06-01
GC0000214A (en) 2006-03-29
DE60020883T2 (de) 2006-03-23
MY128003A (en) 2007-01-31
IL149622A0 (en) 2002-11-10
AU2163901A (en) 2001-06-18
PL364814A1 (en) 2004-12-13
TWI276629B (en) 2007-03-21
AR031083A1 (es) 2003-09-10
PT1244625E (pt) 2005-09-30
CZ20022352A3 (cs) 2003-05-14
JO2281B1 (ar) 2005-09-12
WO2001042215A1 (en) 2001-06-14
CN1402709A (zh) 2003-03-12
CN1196682C (zh) 2005-04-13
NO20022650L (no) 2002-06-05
CO5080771A1 (es) 2001-09-25
IL149622A (en) 2006-12-10
BR0016172A (pt) 2002-08-20
ES2243335T3 (es) 2005-12-01
CA2392566A1 (en) 2001-06-14
DE60020883D1 (de) 2005-07-21
DK1244625T3 (da) 2005-10-10
HUP0203735A3 (en) 2005-03-29
EP1244625A1 (en) 2002-10-02
JP2003516392A (ja) 2003-05-13
HUP0203735A2 (hu) 2003-03-28
UY26470A1 (es) 2001-05-31
KR20020060256A (ko) 2002-07-16
YU40502A (sh) 2005-03-15
HRP20020467A2 (en) 2004-04-30
PE20010960A1 (es) 2001-09-22
RU2270193C2 (ru) 2006-02-20

Similar Documents

Publication Publication Date Title
NO322910B1 (no) 4-Pyridyl-N-acyl-L-fenylalaniner, anvendelse av disse som medikamenter, farmasoytiske preparater inneholdende slike forbindelser og fremgangsmate for fremstilling av disse.
US6388084B1 (en) 4-pyridinyl-n-acyl-l-phenylalanines
US6380387B1 (en) 4-Pyrimidinyl-n-acyl-l phenylalanines
JP3824935B2 (ja) 4−ピリミジニル−n−アシル−l−フェニルアラニン
US6423728B1 (en) Heterocyclic thioamide derivatives
SK140994A3 (en) Imidazopyridazines, method of their production and pharmaceutical preparation on their base and method of their production
EP0595610A1 (en) Benzo-fused lactams
CZ2000597A3 (cs) N-Aroylfenylalaninové deriváty